<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03827564</url>
  </required_header>
  <id_info>
    <org_study_id>1919-802-019</org_study_id>
    <nct_id>NCT03827564</nct_id>
  </id_info>
  <brief_title>Goblet Cell Degranulation Produced by Intranasal Tear Neurostimulator (ITN) in Dry Eye Disease</brief_title>
  <official_title>Goblet Cell Degranulation Produced by Nasal Neurostimulation: A Randomized, Controlled Study in Patients With Dry Eye Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate goblet cell degranulation following acute use of the
      Intranasal Tear Neurostimulator in participants with dry eye.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 24, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in goblet cell degranulation post-intranasal use of the ITN at the Application visit compared to without use of the ITN at the Screening visit</measure>
    <time_frame>Screening (Day -60 to Day -30) to Application Visit (Day 0)</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Dry Eye Syndromes</condition>
  <arm_group>
    <arm_group_label>ITN [TrueTear®] - Intranasal Application</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intranasal application of the ITN. Single application at application visit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ITN [TrueTear®] - Extranasal Application</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Extranasal application of the ITN. Single application at application visit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Intranasal Tear Neurostimulator (ITN) [TrueTear®]</intervention_name>
    <description>The ITN applies a small electrical current to the nasal cavities to gently activate the body's natural tear production system.</description>
    <arm_group_label>ITN [TrueTear®] - Extranasal Application</arm_group_label>
    <arm_group_label>ITN [TrueTear®] - Intranasal Application</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Capable of giving verbal and signed informed consent, which includes compliance with
             the requirements and restrictions listed in the ICF and in this protocol

          -  Have not worn contact lenses for at least 7 days prior to the screening visit and are
             willing to forego the use of contact lenses for the duration of the study

          -  The participant should be literate, able to speak English, and able to complete
             questionnaires independently

        Exclusion Criteria:

          -  Chronic or recurrent epistaxis, coagulation disorders or other conditions that, in the
             opinion of the investigator, may lead to clinically significant increased bleeding

          -  Nasal or sinus surgery (including history of application of nasal cautery) or
             significant trauma to these areas

          -  Cardiac demand pacemaker, implanted defibrillator or other implanted electronic device

          -  Corneal transplant in either or both eyes

          -  Current enrollment in an investigational drug or device study or participation in such
             a study within 30 days of entry into this study

          -  Women who are pregnant, planning a pregnancy, or nursing throughout the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Pflugfelder, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine, Department of Ophthalmology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trial Registry Team</last_name>
    <phone>877-277-8566</phone>
    <email>IR-CTRegistration@Allergan.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Baylor College of Medicine - Department of Ophthalmology</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-3411</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>713-798-6100</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 31, 2019</study_first_submitted>
  <study_first_submitted_qc>January 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 1, 2019</study_first_posted>
  <last_update_submitted>January 27, 2020</last_update_submitted>
  <last_update_submitted_qc>January 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dry Eye Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Allergan will share de-identified patient-level data and study-level data including protocols and clinical study reports for phase 2 - 4 trials completed after 2008 that are registered to ClinicalTrials.gov or EudraCT, have received regulatory approval in the United States and/or the European Union in a given indication and the primary manuscript from the trial has been published. To request access to the data, the researcher must sign a data use agreement and any shared data is to be used for non-commercial purposes. More information can be found on http://www.allerganclinicaltrials.com/.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>After having received regulatory approval in the United States and/or the European Union in a given indication and the primary manuscript from the trial has been published.</ipd_time_frame>
    <ipd_access_criteria>To request access to the data, the researcher must sign a data use agreement and any shared data is to be used for non-commercial purposes.</ipd_access_criteria>
    <ipd_url>http://www.allerganclinicaltrials.com/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

